OCEA: Ocean Biomedical Inc Company Value to Net Income
Ocean Biomedical, Inc. is driving innovation in immunology and oncology through scientific alliances with universities, creating synergy to bring drugs to market. The quotes provided below, where the P/E ratio is -0.10, link these developments to management's strategy for the accelerated licensing of ready-made technologies. The company's operations are strictly regulated by FDA standards, which limits its eco-strategy solely to the proper disposal of biomaterials.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_OCEA_-_Ocean-Biomedical-Inc._-_PE-Multiple "OCEA: Ocean Biomedical, Inc. Business Payback Period 04/28/2023 - 04/26/2025 | 👁️GURU.Markets👁️")
Analytical breakdowns for Ocean Bio (OCEA)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Ocean Biomedical, Inc.|OCEA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ocean Biomedical Corp|OCEA - Company Debts|Debt to Book Value Ratio Ocean Biomedical, Inc.|OCEA - Company Long-Term Debts|Short-Term Debt Ocean Biomedical|Immediate Liquidity oceanbiomedical.com
- earnings and market multiples details:
OCEA - Net Profit|Future Profit Ocean Biomedical, Inc.|OCEA - P/E Multiple|Projected Price to Earnings Ratio Ocean Biomedical Inc|OCEA - PEG Multiple|EV/EBITDA Multiple Ocean Biomedical, Inc.|OCEA - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Ocean Biomedical|OCEA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months oceanbiomedical.com|OCEA - Earnings growth in current year|Net earnings per share growth forecast for next year Ocean Biomedical, Inc.
Comprehensive company analysis:oceanbiomedical.com OCEA
Portfolio managers are closely monitoring the commercialization efficiency of Ocean Biomedical, Inc. (OCEA) scientific developments. The P/E ratio reflects the market value of a single unit of net profit, measuring the extent to which investors are overpaying for future growth. Analyzing the current P/E of the business allows for the identification of valuation overheating within an academic R&D model. The trend of this indicator signals a risk of correction should margins decline. This confirms the stability of the biotech's capitalization.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|ABCL - Price to Earnings Ratio|Market Cap to Earnings Tourmaline|PGEN: P/E Multiple|Price to Earnings Ratio pharming.com|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|Market Cap to Earnings Upstream Bio, Inc. UPB|P/E Multiple ZBIO|P/E Multiple Immunome Bio (IMNM)|Price to Earnings Ratio Gossamer Bio, Inc. GOSS|KALV: Price to Earnings Multiple|SEPN: Price to Earnings Ratio|Company Value to Net Income PVLA (Pieris Pharma)|SVRA: P/E Multiple|RIGL (Rigel Corp) - Price to Earnings Ratio|ANAB (AnaptysBio, Inc.) - P/E Multiple|astriatx.com (ATXS) - Business Payback Period|Price to Earnings Ratio enGene (ENGN)|RAPT - Market Cap to Earnings|Price to Earnings Ratio Aerovate Therapeutics JBIO|ACRS - Price to Earnings Ratio|Kyverna Therapeutics - P/E Multiple|Market Cap to Earnings tizianalifesciences.com|CABA: P/E Multiple|Price to Earnings Multiple VTYX|THTX (Theratechnologies Inc) - P/E Multiple|Avalo Therapeutics Inc (AVTX) - Business Payback Period|P/E Multiple ELDN|Price to Earnings Ratio agenusbio.com AGEN|P/E Multiple CLYM (Climb Bio)|P/E Multiple Zura Bio Ltd ZURA|ATYR - Price to Earnings Ratio|ADAG: Price to Earnings Ratio|IMA (ikenaoncology.com) - Price to Earnings Ratio|Shattuck Labs - Company Value to Net Income|EQ (Equillium Inc) - P/E Multiple|Connect Pharma (CNTB) - Business Payback Period|Price to Earnings Ratio Immunic, Inc. (IMUX)|atarabio.com - Price to Earnings Multiple|P/E Multiple IFRX (InflaRx)|XFOR - Price to Earnings Ratio|ACET: Price to Earnings Ratio|Business Payback Period Celularity Inc. CELU|INmune Bio Corp (INMB) - Price to Earnings Ratio|Market Cap to Earnings Barinthus Biotherapeutics Corp (BRNS)|KZR (Kezar Life Sciences) - P/E Multiple|Price to Earnings Ratio sabbiotherapeutics.com (SABS)|P/E Multiple AKTX|ENLV - Market Cap to Earnings|P/E Multiple QTTB (Q32 Bio)|P/E Multiple GeoVax Corp GOVX|EDSA - Price to Earnings Ratio|Market Cap to Net Income IBIO|CARM: P/E Multiple|XTL Biopharmaceuticals Ltd - Company Value to Net Income|BOLT (Bolt Biotherapeutics Inc.) - P/E Multiple|P/E Multiple HCW Biologics Inc|Price to Earnings Ratio Aptevo Therapeutics (APVO)|AIM (AIM ImmunoTech, Inc.) - Company Value to Net Income|Price to Earnings Ratio Aditxt, Inc. ADTX|GRI - Price to Earnings Ratio|XORTX - P/E Multiple|HIND - P/E Multiple|REVB (Revelation Biosciences) - Price to Earnings Ratio|indaptusrx.com - Company Value to Net Income|SCNI (Scinai Immunotherapeutics Ltd.) - P/E Multiple|CalciMedica Corp (CALI) - Business Payback Period|Price to Earnings Ratio Affimed (AFMD)|Price to Earnings Ratio allakos.com ALLK|Price to Earnings Ratio HOOKIPA Pharma HOOK|IGMS - Price to Earnings Ratio|ITOS: Price to Earnings Ratio|TCBP - P/E Multiple|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
